Imjudo 300 mg/15 mL (20 mg/mL) injection Images
Generic Name: tremelimumab
This medication has been identified as Imjudo 300 mg/15 mL (20 mg/mL) injection. It is supplied by AstraZeneca.
Imjudo is used in the treatment of Hepatocellular Carcinoma; Non-Small Cell Lung Cancer and belongs to the drug class anti-CTLA-4 monoclonal antibodies. Imjudo 300 mg/15 mL (20 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Imjudo
- Generic Name
- tremelimumab
- Strength
- 300 mg/15 mL (20 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Anti-CTLA-4 monoclonal antibodies
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- AstraZeneca
- National Drug Code (NDC)
- 00310-4535
More about Imjudo (tremelimumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-CTLA-4 monoclonal antibodies
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
